Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Ostergaard

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Thrombosis Research|March 1, 1991
Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteersP C Pedersen, P B Ostergaard, U Hedner, et al.
Thrombosis and Haemostasis|September 7, 1992
Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparinH I Kristensen, P B Ostergaard, O Nordfang, et al.
Thrombosis and Haemostasis|June 30, 1986
A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparinV Diness, J I Nielsen, P C Pedersen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|April 11, 2000
The link between high-fat meals and postprandial activation of blood coagulation factor VII possibly involves kallikreinL F Larsen, P Marckmann, E M Bladbjerg, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 1, 1994
Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteersJ Holst, B Lindblad, D Bergqvist, et al.
Thrombosis Research|December 1, 1993
Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosisJ Holst, B Lindblad, E Wedeberg, et al.
Thrombosis and Haemostasis|April 1, 1996
Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparinJ Holst, B Lindblad, S E Matthíasson, et al.
Thrombosis Research|February 15, 1996
Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitorJ Holst, B Lindblad, G Westerlund, et al.
Thrombosis and Haemostasis|February 1, 1994
Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparinJ Holst, B Lindblad, D Bergqvist, et al.
Haemostasis|March 1, 1993
Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis modelJ Holst, B Lindblad, D Bergqvist, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Thrombosis Research|March 1, 1991
Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteersP C Pedersen, P B Ostergaard, U Hedner, et al.
Thrombosis and Haemostasis|September 7, 1992
Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparinH I Kristensen, P B Ostergaard, O Nordfang, et al.
Thrombosis and Haemostasis|June 30, 1986
A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparinV Diness, J I Nielsen, P C Pedersen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|April 11, 2000
The link between high-fat meals and postprandial activation of blood coagulation factor VII possibly involves kallikreinL F Larsen, P Marckmann, E M Bladbjerg, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 1, 1994
Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteersJ Holst, B Lindblad, D Bergqvist, et al.
Thrombosis Research|December 1, 1993
Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosisJ Holst, B Lindblad, E Wedeberg, et al.
Thrombosis and Haemostasis|April 1, 1996
Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparinJ Holst, B Lindblad, S E Matthíasson, et al.
Thrombosis Research|February 15, 1996
Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitorJ Holst, B Lindblad, G Westerlund, et al.
Thrombosis and Haemostasis|February 1, 1994
Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparinJ Holst, B Lindblad, D Bergqvist, et al.
Haemostasis|March 1, 1993
Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis modelJ Holst, B Lindblad, D Bergqvist, et al.
Pageof 3